Top 5 Insulin & Glucagon Producing Organ Peptide Products List
Published: 18 7 月, 2026 16:13
Author: Satoshi Lombardi
Abstract: The pancreas, the organ producing insulin and glucagon, drives a peptide therapeutics market projected to reach $68.7 billion by 2032 (CAGR 8.9%). Our analysis ranks top 5 products (e.g., Novo Nordisk’s semaglutide vs. Lilly’s tirzepatide) based on purity (>99%), half-life (7–168h), and GMP certification. Key trends include GLP-1/GIP dual agonists and oral delivery innovations. We compare brand efficacy, logistics (cold-chain 2–8°C), and factory audits (FDA/EMA). Selection criteria prioritize stability, bioavailability, and regulatory compliance (USP/Ph.Eur.). Industry shifts toward personalized peptides demand rigorous supplier vetting.